People with type 1 diabetes who are taking SGLT-2 inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin and Ertugliflozin) are at risk of developing diabetic ketoacidosis during any illness. During the Coronavirus epidemic there are some additional safety considerations in treating DKA in patients with COVID-19. In the absence of high quality evidence to guide us, ABCD believes that clinicians may wish to discuss these medications with their patients and possibly mutually agree to stop SGLT-2 inhibitors and control blood glucose by adjusting insulin doses.

We are currently seeking applications for two new ABCD committee members.

All members of ABCD are eligible for application and should be proposed and seconded by other current members of ABCD.

To apply simply complete the online form, the closing date is Wednesday 3rd June 2020.

A National Stakeholders Covid-19 Response Group Interim Guidance developed by JBDS-IP, ABCD, Diabetes UK and diabetes FRAIL

This guidance is designed to support clinical decision-making in care.

Practical guidance for managing inpatient hyperglycaemia during COVID-19

Concise advice on inpatient diabetes during COVID-19 - A guideline for managing DKA using subcutaneous insulin where intravenous insulin infusion is not possible.

The ABCD Exenatide Audit

REJ Ryder on behalf of the ABCD Exenatide Audit Contributors

City Hospital, Birmingham, UK

A National Stakeholders Covid-19 Response Group Interim Guidance developed by JBDS-IP, ABCD, Diabetes UK and diabetes FRAIL

This guidance is designed to support clinical decision-making in care homes. As such, the guidance will take into account the availability of skilled personnel, access to monitoring of blood glucose (sugar) and ketones, fluid administration limits, and overall level of care likely to be available.

This guidance was prepared by a multidisciplinary stakeholder group in order to:

In the midst the Covid-19 pandemic ABCD is uniquely placed to obtain a “snap shot” of what life as a Diabetologist looks like now. Equipped with this information we will be able to feed back and influence bodies as Royal College of Physicians, their Training Board (JRCPTB) and NHS England.

NICE guidelines versus clinical practice – GLP-1 receptor agonists in type 2 diabetes: the ABCD nationwide audits

KY Thong¹, P Sen Gupta², ML Cull², KA Adamson³, DS Dove⁴, SV Rowles⁵, S Tarpey⁵, C Duncan⁶,J Chalmers⁶, R Harper⁷, P McDonald⁷, U Brennan⁷, C Walton⁸, REJ Ryder² on behalf of the ABCD Nationwide exenatide^* and liraglutide^† audit contributors